KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Operating Leases: 2021-2025

Historic Operating Leases for Castle Biosciences (CSTL) over the last 4 years, with Sep 2025 value amounting to $25.3 million.

  • Castle Biosciences' Operating Leases rose 72.23% to $25.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.3 million, marking a year-over-year increase of 72.23%. This contributed to the annual value of $14.3 million for FY2024, which is 1.21% up from last year.
  • Latest data reveals that Castle Biosciences reported Operating Leases of $25.3 million as of Q3 2025, which was down 0.30% from $25.4 million recorded in Q2 2025.
  • Over the past 5 years, Castle Biosciences' Operating Leases peaked at $25.4 million during Q2 2025, and registered a low of $6.5 million during Q2 2022.
  • Moreover, its 3-year median value for Operating Leases was $14.0 million (2025), whereas its average is $15.7 million.
  • Data for Castle Biosciences' Operating Leases shows a peak YoY soared of 91.77% (in 2023) over the last 5 years.
  • Castle Biosciences' Operating Leases (Quarterly) stood at $6.9 million in 2021, then spiked by 67.14% to $11.5 million in 2022, then increased by 22.89% to $14.2 million in 2023, then climbed by 1.21% to $14.3 million in 2024, then spiked by 72.23% to $25.3 million in 2025.
  • Its Operating Leases stands at $25.3 million for Q3 2025, versus $25.4 million for Q2 2025 and $14.0 million for Q1 2025.